Main Product Image

Ruxotor 10 mg (Ruxolitinib Phosphate)

Subcategory: Medicine

Ruxotor 10 mg is an oral medication that contains Ruxolitinib Phosphate, a targeted therapy primarily used in the management of certain blood-related and immune-mediated disorders. Ruxolitinib belongs to a class of medicines known as Janus Kinase (JAK) inhibitors, which work by regulating abnormal signaling pathways involved in inflammation and uncontrolled cell growth.

Originally developed through research supported by companies such as Novartis and Incyte Corporation, Ruxolitinib has become an important treatment option in modern hematology and immunology.

Composition and Dosage Form

Ruxotor 10 mg contains 10 mg of Ruxolitinib Phosphate in tablet form. It is designed for oral administration and is usually supplied in blister packs or bottles to ensure proper protection and dosing accuracy.

Each tablet is formulated to provide consistent absorption and therapeutic effect when taken as prescribed by a healthcare professional.

Mechanism of Action

Ruxolitinib works by inhibiting JAK1 and JAK2 enzymes, which play a crucial role in the JAK-STAT signaling pathway. This pathway is responsible for transmitting signals from growth factors and cytokines to the cell nucleus.

In certain diseases, this pathway becomes overactive, leading to:

Excessive inflammation

Abnormal blood cell production

Immune system dysfunction

By blocking JAK1 and JAK2, Ruxotor helps reduce these abnormal signals, leading to better control of symptoms and disease progression.

Therapeutic Uses

Ruxotor 10 mg is commonly prescribed for the treatment of:

1. Myelofibrosis

A chronic bone marrow disorder that interferes with normal blood cell production. Ruxolitinib helps reduce spleen enlargement, fatigue, and other systemic symptoms.

2. Polycythemia Vera

A condition characterized by excessive red blood cell production. Ruxotor helps regulate blood counts and lower the risk of complications.

3. Graft-Versus-Host Disease (GVHD)

Used in patients who do not respond adequately to steroid therapy, helping control immune reactions after stem cell transplantation.

4. Other Inflammatory Disorders

In some cases, doctors may prescribe Ruxolitinib for selected autoimmune or inflammatory conditions under specialist supervision.

Dosage and Administration

The dosage of Ruxotor 10 mg depends on:

Patient’s age and weight

Medical condition

Blood test results

Overall health status

Typical guidelines include:

Taken once or twice daily, with or without food

Tablets should be swallowed whole with water

Do not crush or chew unless advised

Dosage adjustments may be required based on response and laboratory monitoring.

Benefits of Ruxotor 10 mg

Key advantages of Ruxotor include:

Effective symptom relief in chronic blood disorders

Reduction of spleen size in myelofibrosis

Improved quality of life

Targeted mechanism with focused action

Well-established clinical evidence

Many patients experience reduced fatigue, improved appetite, and better physical functioning with regular use.

Possible Side Effects

Like all prescription medicines, Ruxotor may cause side effects. Common ones include:

Headache

Dizziness

Fatigue

Anemia (low red blood cells)

Thrombocytopenia (low platelets)

Increased risk of infections

Less common but serious side effects may include liver problems, severe infections, or changes in cholesterol levels. Regular medical follow-up is essential.

Precautions and Warnings

Before using Ruxotor 10 mg, inform your doctor if you have:

Liver or kidney disease

Active infections

History of tuberculosis

Weak immune system

Pregnancy or breastfeeding

Patients should avoid live vaccines during treatment and report any signs of infection immediately.

Storage and Handling

Store at room temperature (below 25°C)

Keep away from moisture and sunlight

Store out of reach of children

Do not use expired tablets

Proper storage ensures the medicine maintains its effectiveness.

Conclusion

Ruxotor 10 mg (Ruxolitinib Phosphate) is a highly effective targeted therapy for managing myeloproliferative and immune-related disorders. Inhibiting key enzymes in the JAK-STAT pathway, it helps control disease activity, reduce symptoms, and improve patients’ quality of life.

When used under medical supervision with regular monitoring, Ruxotor provides a reliable and modern treatment option for individuals suffering from chronic blood and inflammatory conditions.

Messenger WhatsApp Call